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PGAP2 Mutations, Affecting
the GPI-Anchor-Synthesis Pathway, Cause
Hyperphosphatasia with Mental Retardation Syndrome
Peter M. Krawitz,1,2,3 Yoshiko Murakami,4,5 Angelika Rieß,6 Marja Hietala,7 Ulrike Kru¨ger,1 Na Zhu,1
Taroh Kinoshita,4,5 Stefan Mundlos,1,2,3 Jochen Hecht,2,3 Peter N. Robinson,1,2,3,8,* and Denise Horn1,8,*
Recently, mutations in genes involved in the biosynthesis of the glycosylphosphatidylinositol (GPI) anchor have been identified in a
new subclass of congenital disorders of glycosylation (CDGs) with a distinct spectrum of clinical features. To date, mutations have
been identified in six genes (PIGA, PIGL, PIGM, PIGN, PIGO, and PIGV) encoding proteins in the GPI-anchor-synthesis pathway in in-
dividuals with severe neurological features, including seizures, muscular hypotonia, and intellectual disability. We developed a diag-
nostic gene panel for targeting all known genes encoding proteins in the GPI-anchor-synthesis pathway to screen individuals matching
these features, and we detected three missense mutations in PGAP2, c.46C>T, c.380T>C, and c.479C>T, in two unrelated individuals
with hyperphosphatasia with mental retardation syndrome (HPMRS). The mutations cosegregated in the investigated families.
PGAP2 is involved in fatty-acid GPI-anchor remodeling, which occurs in the Golgi apparatus and is required for stable association be-
tween GPI-anchored proteins and the cell-surface membrane rafts. Transfection of the altered protein constructs, p.Arg16Trp
(NP_001243169.1), p.Leu127Ser, and p.Thr160Ile, into PGAP2-null cells showed only partial restoration of GPI-anchored marker pro-
teins, CD55 and CD59, on the cell surface. In this work, we show that an impairment of GPI-anchor remodeling also causes HPMRS
and conclude that targeted sequencing of the genes encoding proteins in the GPI-anchor-synthesis pathway is an effective diagnostic
approach for this subclass of CDGs.In the last 2 years, individuals with characteristic pheno-
typic features including severe neurological abnormalities
were reported to have defects in the GPI-anchor-biosyn-
thesis pathway, representing a new subclass of congenital
disorders of glycosylation (CDGs).1 Mutations in PIGV
(MIM 610274) and PIGO (MIM 614730) were shown to
cause hyperphosphatasia with mental retardation syn-
drome (HPMRS [MIM 239300 and 214749]), which is
also referred to as Mabry syndrome.2–7 Individuals with co-
loboma, congenital heart disease, ichthyosiform derma-
tosis, mental retardation, and ear anomalies syndrome
(CHIME [MIM 280000]), also known as Zunich neuroecto-
dermal syndrome, were reported to have mutations in
PIGL (MIM 605947).8 A hypomorphic promoter mutation
in PIGM (MIM 610273) causes portal venous thrombosis
and absence seizures (MIM 610293).9 Germline mutations
in PIGN (MIM 606097) and PIGA (MIM 311770) cause
severe syndromes with multiple congenital anomalies, hy-
potonia, and seizures (MCAHS), now referred to as
MCAHS1 (MIM 614080) and MCAHS2 (MIM 300868).
Similar to other disorders of glycosylation, disorders
caused by mutations interfering with the GPI-anchor
pathway are characterized by a remarkable phenotypic
diversity whereby the clinical impact seems to depend
on the severity of the mutation.10 To date, all identified
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Although distinct phenotypic features seem to be exclusive
to single genes or are shared only by a subgroup, the
phenotypic features of intellectual disability, seizures,
andmuscular hypotonia are present in amajority of the in-
dividuals described so far.
We therefore included 13 individuals with intellectual
disability and elevated serum alkaline phosphatese (ALP)
in a mutation screen of all genes encoding proteins in
the GPI-anchor-biosynthesis pathway. In these individ-
uals, mutations in PIGV had been excluded by Sanger
sequencing. The Charite´ University Medicine ethics board
approved this study, and we obtained informed consent
from the responsible persons (parents) on behalf of all
study participants. In this work, we report the molecular
findings in two unrelated individuals (II-1 of family A
and II-1 of family B in Figure 1) with the clinical diagnosis
of HPMRS but without identifiable mutations in PIGV and
PIGO (Table 1). We performed targeted capture sequencing
in the affected individuals of families A and B. Family A is
of Finnish origin, and family B is of Turkish origin. For tar-
geted enrichment of exons of all known genes involved in
GPI-anchor synthesis, we designed a customized SureSelect
library (Agilent) comprising 1,202 different 120 bp oligo-
nucleotide baits in total (see Supplemental Data, available
online). Genomic DNA of both individuals was enrichedizin, 13353 Berlin, Germany; 2Berlin Brandenburg Center for Regenerative
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Figure 1. Phenotypic Features of HPMRS
Associated with Mutations in PGAP2
(A and B) Face of individual A from family
A at the ages of 3 (A) and 28 years (B).
(C) Normal-appearing fingernails of the
affected individual in family A.
(D and E) Facial dysmorphism of the
affected individual in family B at the age
of 2 years includes wide palpebral fissures,
a short nose with a broad nasal bridge, a
tented upper lip, and a small jaw.
(F) Distal tapering of fingers and mild nail
hypoplasia of the fifth digit of the affected
individual in family B.for this target region according to the manufacturer’s
protocol, and this was followed by single-read cluster
generation on the Cluster Station (Illumina). The captured,
purified, and clonally amplified library was then
sequenced on an Illumina Genome Analyzer IIx and map-
ped to the human reference sequence GRCh37, resulting
in a mean coverage of above 300-fold for all exons and
more than 10-fold for >95% of the target region (see
Figure S1). Variants were detected with SAMtools,12
annotated with ANNOVAR,13 and further analyzed in Gen-
eTalk.14 In individual A, we detected a total of 30 single-
nucleotide variants with respect to the reference sequence
GRCh37, and these included 14 missense mutations, 9 of
which were homozygous (Table S2). Three variants
not listed in dbSNP135 coded for heterozygous missense
mutations: one in PIGZ, c.214G>C (RefSeq accession num-
ber NM_025163.2) (p.Asp72His) (RefSeq NP_079439.2),
and two in PGAP2, c.[46C>T];[479C>T] (RefSeq
NM_001256240.1) (p.[Arg16Trp];[p.Thr160Ile]) (RefSeq
NP_001243169.1). In individual B, we observed 32 vari-
ants, 17 synonymous and 15 homozygous (Table S3).
Only one homozygous missense mutation in PGAP2
(c.380T>C [p.Leu127Ser] [RefSeq NM_001256240.1]) was
not listed in dbSNP135.
All missense mutations (c.46C>T, c.380T>C, and
c.479C>T) were analyzed for segregation in available fam-
ily members (Figure 2). In family A, the mother is a carrier
for c.46C>T. The healthy brother is a carrier of c.479C>T,
allowing us to infer the same genotype for the father, who
was not available for analysis. In family B, both parents
and one healthy brother are carriers of c.380T>C, whereas
one healthy brother has the wild-type sequence.
Individual II-1 of family A is the first child of non-
consanguineous Finnish parents. Her younger brother is
healthy. There is a family history of febrile seizures and ep-The American Journal of Humanilepsy, but not of intellectual
disability. Her neonatal period was
uneventful, and postnatal develop-
ment was normal. She started to
walk at the age of 18 months, and
her initial speech development was
normal. At that age, her facial dys-
morphism was subtle in that shehad only a broad nasal bridge and a tented upper lip
(Figure 1A and Table 1). From the age of 8 months to the
age of 2.5 years, she suffered from febrile seizures. At the
age of 8 years, she began to have tonic-clonic seizures,
which responded well to valproic acid. At the age of 22
years, her antiepileptic medication was discontinued and
she showed no recurrence of seizures. A physical examina-
tion at 28 years revealed a height, weight, and head
circumference within the normal range. There was no
distinctive facial dysmorphism (Figure 1B). Her fingernails
appeared to be normal (Figure 1C). A hand radiograph was
not available. Individual II-1 of family A started at an ordi-
nary school but has received special education since the
age of 12 years, and she currently works in supported
employment.
Her serum ALP activity was measured only once during
childhood when she was 10 years old. This elevated value
(3,470 U/l; the normal range for the corresponding age is
105–400 U/l) was interpreted as a laboratory mistake.
When she was 28 years old, ALPwasmeasured again. These
values were repeatedly elevated (2,107–2,448 U/l; the
normal range is 35–105 U/l).
Individual II-1 of family B is the third child of consan-
guineous parents of Turkish origin. The family history is
unremarkable. Birth length and weight were normal, and
the occipitofrontal head circumference (OFC) at birth
was 33 cm (2 SDs). After birth, physical examination
revealed a median cleft palate, which was surgically cor-
rected. Chronic constipation and acute illeus led to the
diagnosis of Hirschsprung disease, which was histological-
ly confirmed and surgically repaired. Examinations of this
tissue or other tissues for intracellular inclusions were not
performed. Echocardiography showed an atrial septal
defect. Cranial computed tomography revealed hypoplasia
of the corpus callosum.Genetics 92, 584–589, April 4, 2013 585
Table 1. Summary of Clinical Findings in HPMRS-Affected Individuals Carrying PGAP2, PIGO and PIGV Mutations
Features
Human Phenotype
Ontology ID11
Affected Individual
in Family A
Affected Individual
in Family B
Individuals with PIGO
Mutations (n ¼ 3)
Individuals with PIGV
Mutations (n ¼ 14)a
Sex NA female male females 9 females and 5 males
Age at last assessment NA 28 years 3.5 years 20 months to 15 years 7 months to 17 years
Origin NA Finnish Turkish European German, Maroccan,
Dutch, Polish, British,
and European American
Height (SD) NA 0.9 þ0.6 1.4 to 4.2 normal in 13/14
Weight (SD) NA normal 1.0 þ0.6 to 3.3 normal in 13/14
OFC (SD) NA normal 4.5 þ0.7 to 5.5 normal in 12/14
Hyperphoshatasiab HP:0003155 þ þ 3/3 14/14
Intellectual disabilityb HP:0001263 mild þ 3/3 14/14
Age at walking NA 18 months no walking delayed delayed
Delayed speech and
language development
HP:0000750  þ 3/3 14/14
Muscular hypotonia HP:0001252  þ 3/3 11/12
Seizures HP:0001250 þ þ 1/3 9/12
Apparent hypertelorism HP:0000316  þ 3/3 þ
Long palpebral fissures HP:0000637  þ 3/3 þ
Broad nasal bridge HP: 0000431 þ þ 3/3 þ
Broad nasal tip HP:0000455  þ 3/3 þ
Tented upper lip
vermilion
HP:0010804 þ þ 3/3 þ
Brachytelephalangy HP:0009882 normal appearing
fingernails
short fifth fingernail 3/3 14/14
Anorectal abnormalities
and/or constipation
HP:0002025
(anal stenosis)
 þ 3/3 6/12
Aganglionic megacolon HP:0002251  þ 1/3 2/14
Heart defect HP:0001631  þ þ 1/14
Cleft palate HP:0000175  þ 0/3 3/14
Hearing impairment HP:0000365  þ 0/3 3/14
The following abbreviations are used: NA, not applicable; and OFC, occipitofrontal head circumference.
aNot all features were documented in the reported individuals.
bConsistent features.The boy’s psychomotor development was severely de-
layed. At the age of 3.5 years, he was still not able to sit,
stand, or walk. At the age of 2 years, he had no speech.
Since he was 7 months old, he has suffered from myoc-
lonic and tonic-clonic seizures, which have responded
well to anticonvulsants. Electroencephalography investi-
gations indicated multifocal sharp waves. Brainstem audi-
tory-evoked response demonstrated sensorineural hearing
loss. Ophthalmologic examination gave normal results.
Physical examination of this 3.5-year-old male showed a
height of 104 cm (þ0.6 SD), a weight of 14 kg (1 SD),
marked secondary microcephaly and a head circumference
of 45 cm (4.5 SDs), scoliosis, and severemuscular hypoto-
nia (Table 1). Facial dysmorphism included wide palpebral
fissures and a wide mouth (Figures 1D and 1E). His fingers
showed broad fingernails and a bilateral hypoplastic fifth586 The American Journal of Human Genetics 92, 584–589, April 4, 2fingernail (Figure 1F). ALP activity was elevated in repeated
tests (2,022 U/l; the normal range is 120–320 U/l for the
corresponding age). Conventional cytogenetic analysis
gave normal results. Mutations and deletion of ZFHX1B
were excluded for ruling out Mowat-Wilson syndrome
(MIM 235730).
Thus, both affected individuals presented with intellec-
tual disability, seizures of various degrees, and marked
hyperphosphatasia (more than six times the age-adjusted
upper limit of the normal range). In addition, mild
shortness of fingernails was present in individual II-1 of
family B (Table 1).
Whereas individual A, who harbors compound-hetero-
zygous PGAP2mutations, shows only mild manifestations
regarding neurological involvement and physical features,
individual B, who has the homozygous c.380T>C013
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A B Figure 2. Identification and Segregation
of the PGAP2 Mutations
Pedigrees showing segregation of the
HPMRS phenotype with deleterious vari-
ants in PGAP2 in families A (A) and B (B).
Circles represent females, squares repre-
sent males, filled symbols represent
affected individuals, and dots within
the symbols represent heterozygotes. Se-
quence reads show the mutation in short
read alignments visualized in integrative
genome viewer.mutation, is severely affected by seizures, muscular hypo-
tonia, and marked intellectual disability, as well as various
malformations.
In comparison with the specific phenotypic pattern of
all previously reported individuals with PIGV and PIGO
mutations, the phenotype of individual A broadens the
clinical range of HPMRS with the absence of syndrome-
specific minor anomalies and malformations and only a
mild degree of intellectual disability.
PGAP2 is a membrane protein mainly expressed in the
Golgi and is required for reacylation of the lysoform inter-
mediate GPI during fatty-acid remodeling.15 PGAP2 is hy-
pothesized to play a role in the recruitment or recognition
of fatty-acid donor substrate.15
All three identified PGAP2 alterations, p.Arg16Trp,
Leu127Ser, and Thr160Ile, affect evolutionarily highly
conserved amino acid residues (Figure 3) and are predicted
to be deleterious by MutationTaster.16 We therefore
hypothesized that they might impair the function of
PGAP2 (Figure 3). We cloned human PGAP2 (RefSeq
NM_00125640.1) from a cDNA library derived from
Hep3B (a hepatoma cell line) cells, tagged with FLAG at
theN terminus, and subcloned it into pME.17 Altered forms
of PGAP2 were generated by site-directed mutagenesis.
Altered and wild-type PGAP2 plasmids were transfected
by electroporation into human-CD59-expressing PGAP2-
deficient Chinese hamster ovary (CHO) cells that were
derived from aerolysin-resistant clones from chemically
mutagenized CHO cells as previously described.18 The pro-
tein levels of CD55 and CD59, both GPI-anchored pro-
teins, at the cell surface were determined by cell staining
with anti-FLAG and anti-hamster antibodies and analyzed
by flow cytometry (BD FACSCanto II, BD Biosciences) with
Flowjo software (Tommy Digital). In PGAP2-deficient cells,
fatty-acid remodeling is terminated at the lysoform inter-
mediate GPI as a result of a lack of PGAP2-dependent
reacylation. The lysoform GPI-anchored proteins are
transported to the cell surface, where they are cleaved by
a phospholipase D, resulting in the release of GPI-anchored
proteins lacking lipid moiety and a decrease in the cell-The American Journal of Humansurface level of GPI-anchored pro-
teins.15 After transfection, wild-type
PGAP2 restored the levels of CD55
and CD59 at the cell surface moreefficiently than did the p.Arg16Trp, p.Leu127Ser, and
p.Thr160Ile altered forms (Figure 3). Of all three tested
alterations, p.Arg16Trp reduced the levels of CD55 and
CD59 to a lesser degree than did p.Leu127Ser or
p.Thr160Ile. Although it is uncertain whether this result
is relevant for the in vivo situation, it might suggest a less
severe impairment of PGAP2 function and might correlate
with the milder phenotype in individual II-1 of family A.
Elevated secretion of ALP, which is normally GPI
anchored to the cell surface, into the serum leads to hyper-
phosphatasia. The biochemical mechanisms of hyper-
phosphatasia in PGAP2-deficient individuals described in
this study and in PIGV- or PIGO-deficient individuals re-
ported previously are distinct. In PGAP2-deficient cells,
GPI-anchored proteins lacking the lipidmoiety and having
only the glycan moiety of GPI are released because of a
defect in PGAP2-mediated reacylation during fatty-acid ex-
change in the Golgi and the subsequent cleavage by a
phospholipase D after transport to the cell.15,19 In PIGV-
or PIGO-deficient cells, the C-terminal GPI-attachment
signal peptide of the GPI-anchored protein precursor
tentatively acts as a membrane anchor in the endoplasmic
reticulum and is cleaved by GPI transamidase but cannot
be replaced by a GPI anchor because of a lack of mature
GPI synthesis. This abnormality results in the release of
soluble proteins completely lacking GPI moiety.20
In summary, we have identified a homozygous missense
mutation in PGAP2 in an affected individual with the
specific HPMRS phenotype and compound-heterozygous
PGAP2 mutations causing a nonsyndromic intellectual-
disability phenotype in a second individual. These findings
suggest that the clinical range associated with PGAP2
mutations includes severe manifestations of HPMRS and
nonsyndromic and mild intellectual disability. Recent
data from exome-sequencing studies have shown that
mutations of known genes associated with a specific syn-
drome diagnosis might also be identified in nonsyndromic
intellectual disability. This suggests that present syndrome
descriptions are strongly biased toward clinically recogniz-
able phenotypes.21,22Genetics 92, 584–589, April 4, 2013 587
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Figure 3. Reduced Activity of Altered Forms of PGAP2 in Restoring Surface Expression of GPI-Anchored Proteins after Transfection
into PGAP2-Null Cell Lines
PGAP2-deficient CHO cells were transiently transfected with wild-type or altered forms (p.Arg16Trp, p.Thr160Ile [family A], and
p.Leu127Ser [family B]) of pTA Flag-PGAP2 isoform 8 driven by a weak promoter. Restoration of the surface expression was assessed
2 days later by flow cytometry. p.Arg16Trp and p.Thr160Ile detected in family A and p.Leu127Ser detected in family B did not restore
the surface expression of CD59 and CD55 as efficiently as the wild-type PGAP2. The reduction of surface protein levels associated
with p.Arg16Trp was less severe. This correlates with a lower sequence conservation of this position and a milder phenotype in individ-
ual II-1of family A.Molecular and phenotypic characterization of more in-
dividuals with HPMRS will be required for determining
whether there are any differences in the phenotypes
caused by PIGV, PIGO, and PGAP2 mutations. The com-
prehensive sequence analysis of HPMRS cases, as well as
intellectual-disability cases with a suspected GPI-anchor
deficiency indicated by, for example, elevated serum ALP
activity, will help to elucidate the phenotypic spectrum
of mutations affecting this molecular pathway.Supplemental Data
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found with this article online at http://www.cell.com/AJHG.Acknowledgments
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